This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Related letters  • Similar articles in JAMA  Topic Collections  • Journalology/ Peer Review/ Authorship  • Men's Health  • Prostate Disease  • Oncology  • Prostate Cancer  • Statistics and Research Methods  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: In his Editorial about the null results of the SELECT and Physicians' Health Study II clinical trials, Dr Gann¹ raised the important issue of preclinical science in chemopreventive agent development. A critical component of the preclinical development of any candidate cancer chemopreventive agent is the demonstration of its anticarcinogenic efficacy in biologically relevant animal models. Findings of significant chemopreventive activity in such models are key elements of the rational selection of agents for subsequent evaluation in clinical prevention trials.

Several studies using animal models of prostate cancer have examined the preventive efficacy of the agents tested in the SELECT trial (selenomethionine, -tocopherol, and selenomethionine plus -tocopherol) and the Physicians' Health Study II (-tocopherol) and of selenized yeast, the agent studied in the Nutritional Prevention of Cancer trial.² None of these studies demonstrated significant prostate cancer preventive activity in the rat.^3-5 These negative preclinical model studies have . . . [Full Text of this Article]

Maarten C. Bosland, DVSc, PhD
boslandm@uic.edu
Department of Pathology
University of Illinois at Chicago

David L. McCormick, PhD
Life Sciences Group
IIT Research Institute
Chicago

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Randomized Trials of Antioxidant Supplementation for Cancer Prevention: First Bias, Now Chance—Next, Cause
Peter H. Gann
JAMA. 2009;301(1):102-103.
EXTRACT | FULL TEXT  

RELATED LETTERS

Antioxidant Supplementation and Cancer Prevention
Paul F. Pinsky
JAMA. 2009;301(18):1878.
EXTRACT | FULL TEXT  

Antioxidant Supplementation and Cancer Prevention—Reply
Peter H. Gann
JAMA. 2009;301(18):1879.
EXTRACT | FULL TEXT